Latest Channel 4 News:
BNP struggles in Brussels
China quake destroys 10,000 homes
Ageing slowed by fewer calories
'Jacko's drug use concerned family'
PM hails solidarity over Iran row

Viagra firm abandons EU action

Updated on 20 November 2008

Source PA News

The makers of anti-impotence drug Viagra have withdrawn their bid to make it available without a prescription.

Drug company Pfizer had wanted to make 50 milligram tablets freely available in the European Union.

But in a letter to the European Medicines Agency (EMEA), Pfizer said it would withdraw the application in the light of concerns from EMEA's Committee for Medicinal Products for Human Use.

A spokeswoman for EMEA said: "One concern was that its use with a lack of proper medical supervision could delay diagnosis of the underlying causes of erectile dysfunction which can include heart disease."

Viagra, the marketing name of the drug sildenafil citrate, overcomes impotence by blocking an enzyme that limits blood flow to the penis.

Rory O'Connor, Pfizer's vice president of Medical and Regulatory Affairs, said: "Sildenafil citrate has a proven safety profile that has been well established in extensive post-marketing studies and in more than 120 clinical trials.

"We will continue to work with regulators in Europe to improve the availability of our medicines to patients and physicians and the benefits they get from our therapies."

These news feeds are provided by an independent third party and Channel 4 is not responsible or liable to you for the same.

Send this article by email


Watch the Latest Channel 4 News

Watch Channel 4 News when you want

Latest Health news

7-day catch-up

Watch Channel 4 News when you want to, from the last week.

Sign up to Snowmail

The day's news from Jon Snow and the team direct to your inbox.

Week in pictures

credit: Reuters

A selection of the best pictures from around the world.

Most watched

Most watched

Find out what's getting people clicking online this week.




Channel 4 © 2009. Channel 4 is not responsible for the content of external websites.